The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to 2033" report has been added to ...

which is a competitor to Illumina technology, like its mid-range NextSeq 2000 sequencer, and the forthcoming launch of Aviti24 that combines sequencing and cell characteristic mapping in a single ...

Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...

Stellaromics, a start-up that uses multiomics technology to help researchers understand the spatial organization of cells and tissues, has raised $80 million in a series B financing. Catalyst4, a ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively. We recently published a list of Jim ...

New Glenn, which has been in development for about a decade, can carry 50 tons (45 metric tons) of payload to low Earth orbit ...

(1) Since Illumina was included in the "Unreliable Entity List", a number of domestic gene sequencing companies have issued replacement and alternative plans; (2) Illumina issued two statements in ...

Last year’s US$118 billion in revenue was the second highest on record for Huawei, and represents 22 per cent year on year growth.

Join us as we gather the world's top young leaders, founders and creators for four days of connecting, learning, teaching and building in our new host city of ...